

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspro.gov

				. 🗸
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/008,361	12/05/2001	Daniel F. Bischof	F-5800	4370
7590 04/27/2004			EXAMINER	
BAXTER HEALTHCARE CORPORATION			BIANCO, PATRICIA	
Bradford R.L. Price, Fenwal Division RLP-30			ART UNIT	PAPER NUMBER
Route 120 and Wilson Road			AKTONII	PAPER NUMBER
Round Lake, IL 60073		3762	12	
			DATE MAILED: 04/27/2004	· ')

Please find below and/or attached an Office communication concerning this application or proceeding.

.~	_		4				
	Application No.	Applicant(s)	7				
	10/008,361	BISCHOF ET AL.					
Office Action Summary	Examiner	Art Unit					
	Patricia M Bianco	3762					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period w Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE!	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 1/22/	<i>'</i> 04.						
<u> </u>	action is non-final.						
3) Since this application is in condition for allowar							
Disposition of Claims							
4) ⊠ Claim(s) 1-34 and 37-65 is/are pending in the a 4a) Of the above claim(s) 1-26,31-33 and 37-65 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 27-30 and 34 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	5 is/are withdrawn from considera	ation.					
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	epted or b) objected to by the liderawing(s) be held in abeyance. See	e 37 CFR 1.85(a).					
11)☐ The oath or declaration is objected to by the Ex	caminer. Note the attached Office	Action or form PTO-152.					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document: 2. Certified copies of the priority document: 3. Copies of the certified copies of the priority document: application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	on No ed in this National Stage					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 12.	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:						

Application/Control Number: 10/008,361

Art Unit: 3762

DETAILED ACTION

Election/Restrictions

This application contains claims 1-26, 31-33 & 37-65 drawn to an invention nonelected with traverse in Paper No. 8. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Response to Amendment

In the amendment filed January 22nd, 2004, claims 27 & 29 were amended, the specification was amended to obviate the objection with respect to the brief description of the drawings, and claims 35 and 46 were cancelled.

Claims 1-34 and 37-65 remain pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

Application/Control Number: 10/008,361

Art Unit: 3762

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 27-30 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Goldhaber et al. (5,269,946) in view of Lin et al. (6,566,046). Goldhaber et al. (hereafter Goldhaber) discloses a system for collecting, separating and filtering whole blood components into storage containers. The system includes 4 bags (16/28/26/34) or containers seen to be equivalent to applicant's primary, platelet unit, plasma unit and auxiliary containers. The containers are integrally coupled to one another by tubing (29/30/32) to form a sterile blood processing set. The system further includes a filter (40) in-line with one of the containers to remove undesired components from the separated blood, such as white blood cells. Goldhaber also discloses that one of the bags may have an appendage or connector (C) that is sized and configured for connecting to additional tubing (see figures). Goldhaber also teaches that additive may be added to one of the containers of the system.

Goldhaber does not explicitly teach that the auxiliary container holding a platelet additive solution comprising an aqueous solution comprising sodium chloride, sodium citrate, sodium acetate, and sodium phosphate for conditioning the platelet concentrate for pathogen inactivation.

Lin et al. (hereafter Lin) teaches of a synthetic platelet storage, or additive, aqueous solution of sodium chloride, sodium citrate, sodium acetate, and sodium

Application/Control Number: 10/008,361

Art Unit: 3762

phosphate. As shown in figure 9B, the solution is held in a bag or container that is part of a whole blood separation system. The solution is used with the photo decontamination of platelets. It would have been obvious to one having ordinary skill in the art at the time the invention was made to select the platelet additive taught by Lin for use in the container system of Goldhaber for mixing the platelets collected within the container for subsequent storage or transfusion, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Kandler et al. 6,326,197 discloses a platelet suspension solution that is an aqueous solution of sodium chloride, sodium citrate, sodium acetate, and sodium phosphate.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Art Unit: 3762

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patricia M Bianco whose telephone number is (703) 305-1482. The examiner can normally be reached on Monday to Friday 9:00-6:30, alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on (703) 308-5181. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

April 16th, 2004

Patricia M Bianco Primary Examiner Art Unit 3762